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Treatment of chronic myeloid leukaemia (CML) with imatinib mesylate and other second/third 
generation c-Abl specific tyrosine kinase inhibitors (TKIs) has significantly extended patient 
survival1. However, TKIs primarily target differentiated cells and do not eliminate leukaemic 
stem cells (LSCs)2-4. Therefore, targeting minimal residual disease (MRD), to prevent acquired 
resistance and/or disease relapse requires identification of novel LSC-selective target(s) that 
can be exploited therapeutically5,6. Given that malignant transformation involves cellular 
metabolic changes, which may in turn render the transformed cells susceptible to specific 
assaults in a selective manner7, we searched for such vulnerabilities in CML LSCs. We 
performed metabolic analyses on both stem cell-enriched (CD34+ and CD34+CD38-) and 
differentiated (CD34-) patient derived CML cells, and compared their signature with that of 
normal counterparts. Combining stable isotope-assisted metabolomics with functional assays, 
we demonstrate that primitive CML cells rely on upregulated oxidative metabolism for their 
survival. We also show that combination-treatment of imatinib with tigecycline, an antibiotic 
that inhibits mitochondrial protein translation, selectively eradicates CML LSCs, both in vitro 
and in a xenotransplantation model of human CML. Our findings provide a strong indication 
for investigating the employment of TKIs in combination with tigecycline to treat CML 
patients with MRD.  
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CML is a myeloproliferative disorder brought about by the chromosomal translocation 
t(9;22)(q34;q11) in a haemopoietic stem cell (HSC)8,9 that drives the expansion of a leukaemic 
clone via BCR-ABL expression, a chimeric onco-protein with a constitutive tyrosine kinase 
activity10. Prolonged treatment with TKIs carries risks of drug toxicity and/or acquired 
resistance, and entails high economic costs to sustain remission. On the other hand, rapid 
relapse in half of the patients is seen after treatment discontinuation11-13. Therefore, to obtain 
potential curative treatments that effectively eradicate CML LSCs, we specifically studied 
patient-derived stem cell-enriched CD34+ CML cells. In culture, proliferating untreated CD34+ 
primary CML cells rapidly lose surface CD34 expression (Supplementary Fig. 1a). Imatinib 
treatment primarily targets differentiated CD34- CML cells for apoptosis, leading to 
enrichment of more primitive CD34+ cells (Supplementary Fig. 1a,b). Consequently, imatinib 
decreases the efficiency of primary CML progenitor cells to form colonies in a short term 
colony forming cell (CFC) assay but, in line with the resistance of CML stem cells to TKI 
treatment, it does not affect the colony forming capacity of CD34+ cell in a long-term culture-
initiating cell (LTC-IC) assay (Supplementary Fig. 1c,d).  
 
Since stem cells can exhibit different metabolic traits compared to their corresponding 
differentiated cells14-16, we metabolically profiled CD34+ and CD34- CML cells derived from 
four patients by recording the steady-state levels of 70 metabolites central to glucose, 
nucleotide, amino acid, fatty acid and energy metabolism, through liquid chromatography-
mass spectrometry (LC-MS). The pattern of metabolites in stem cell-enriched population 
compared to differentiated CML cells revealed a potential increase in lipolysis and fatty acid 
oxidation; we found an increase in glycerol-3-phosphate, carnitine and acylcarnitine 
derivatives, as well as a decrease in free fatty acids, such as oleic and stearic acids (Fig. 1a and 
Supplementary Table 1). Of note, fatty acid oxidation has been associated with the 
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maintenance of HSCs and potentially with leukaemogenesis17,18. In order to validate and further 
substantiate these findings, leukaemic cells were cultured for 24 hours in the presence of 
uniformly 13C16-labelled palmitate, and 13C isotopic enrichment in different palmitate-derived 
metabolites was measured by LC-MS. Substantial enhancement in palmitate-derived carbon in 
tricarboxylic acid (TCA) cycle metabolites and TCA cycle-derived amino acids was recognised 
in CD34+ leukaemic cells in comparison to the differentiated CD34- cells of the same patient 
(Supplementary Fig. 2a). Furthermore, the steady state levels of these metabolites were 
increased in stem cell-enriched CML populations, while lactate levels were decreased (Fig. 1a, 
Supplementary Fig. 2a and Table 1). The steady state levels of aspartate was recently 
recognised as bona-fide indicators of mitochondrial oxidative capacity19-21. Accordingly, CML 
cells derived from four patients presented on average a 3.0-fold increase in mitochondrial 
oxygen consumption rates in CD34+ cells compared to patient-matched CD34- cells. Moreover, 
the complete decrease in oxygen consumption upon ATP synthase inhibition with oligomycin 
demonstrated that the increased oxygen consumption is tightly linked to ATP production in 
these cells (Fig. 1b,c).  However, the increase in the steady state levels of TCA cycle 
metabolites and the derived amino acids could not be solely explained by an increase in fatty 
acid oxidation, as the production of acetyl coenzyme A (CoA) from palmitate does not support 
a net production of TCA cycle metabolites (anaplerosis). 
 
To study oxidative metabolism and anaplerosis in more detail, glucose, an anaplerosis enabling 
metabolite, was traced in leukaemic cells cultured for 24 hours with uniformly 13C6-labelled 
glucose. This revealed that in CD34+ CML cells, TCA cycle metabolites contained a 
significantly larger fraction of isotopologues with 2, 3 or more 13C atoms compared to those in 
CD34- cells (Fig. 1d). The larger fractions of labelled TCA cycle-derived glutamate and 
aspartate observed in CD34+ CML cells confirmed their higher oxidative and anaplerotic 
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activity. Concurrently, CD34+ cells demonstrated a noticeable (although not significant) 
decrease in glucose-derived lactate (13C3-lactate) indicating that pyruvate is indeed more 
effectively shunted towards the TCA cycle (Fig. 1d). Increased acetyl CoA levels produced 
from fatty acid oxidation are predicted to increase the anaplerotic activity of pyruvate 
carboxylase (PC), but potentially to inhibit pyruvate dehydrogenase (PDH) activity. We 
therefore estimated the relative metabolic contribution of both enzymes in 13C6-glucose-
labelled CD34+ compared to CD34- CML cells by assessing the isotopic distribution of the 
nearest detected relevant product (13C3-aspartate for PC and 13C2-citrate for PDH). While no 
change in PDH activity was detected between the two CML cell subsets, the relative activity 
of PC was significantly higher in CD34+ CML cells, further confirming their increased 
oxidative anaplerotic metabolism (Supplementary Fig. 2b,c). 
 
To investigate whether this oxidative phenotype is unique to primitive CML cells, we assessed 
the metabolic profile of CD34+ cells from four CML patients and compared with normal 
haemopoietic CD34+ cells from four donors. Higher steady state levels of carnitine and 
acylcarnitine derivatives and lower levels of free fatty acids, such as oleic and linolenic acids, 
were detected in CD34+ CML cells (Supplementary Fig. 3a and Supplementary Table 2). 
In line with this, the 13C enrichment of citrate, glutamate and aspartate from 13C16-palmitate 
was significantly higher in CD34+ CML cells in comparison to CD34+ normal cells, 
demonstrating that the increase in fatty acid oxidation observed previously is selective to 
CD34+ CML cells (Supplementary Fig. 3b-d). Following incubation with 13C6-glucose, 
the enrichment of glucose-derived 13C isotopes in citrate, glutamate and aspartate was 
significantly higher in CD34+ CML cells compared to their normal counterparts which, 
combined with a significant increase in both PC and PDH relative activity, demonstrated a 
selective increase in glucose oxidation and anaplerosis in the leukaemic cells (Fig. 2a-c, 
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Supplementary Fig. 3e,f). Moreover, the mitochondrial respiration of leukaemic CD34+ 
samples was on average 3.3-fold higher than that of CD34+ normal cells (Fig. 2d,e). As CD34+ 
cell pools contain both stem and progenitor cells, we next verified our findings in a 
CD34+CD38- CML cell population; a rare quiescent sub-population (~5% of total CD34+) that 
is further enriched for LSCs. Flow cytometry analysis of mitochondrial content and 
mitochondrial membrane potential suggested that CML LSCs possess increased mitochondrial 
oxidative functions compared to normal HSCs (Fig. 2f-i). Moreover, 13C6-glucose incubation 
of CD34+CD38- cells isolated from two CML patients revealed that CD34+CD38- CML cells 
contained increased levels of 13C isotopologues for citrate, aspartate and glutamate compared 
to CD34+CD38- normal cells, confirming that CML LSCs have an increased oxidative 
metabolism (Fig. 2j-l and Supplementary Fig. 3g-i). 
 
These findings suggest that in primitive CML cells, mitochondrial oxidative metabolism is 
crucial for production of energy and anabolic precursors and that restraining their 
mitochondrial functions may have a therapeutic benefit. Tigecycline is an FDA-approved 
antibiotic, which inhibits bacterial protein synthesis. Due to the similarity between 
mitochondrial and bacterial ribosomes, it also inhibits the synthesis of mitochondria-encoded 
proteins, all of which are required for the oxidative phosphorylation machinery22. Previous 
reports demonstrated therapeutic efficacy of tigecycline against cancer cells, including primary 
acute myeloid leukaemic cells23 and the oxidative subtype of diffuse large B-cell lymphoma22. 
First, we demonstrated that tigecycline is capable of inhibiting the translation of the 
mitochondrial-encoded proteins MT-CO1 and MT-CO2, but not the nuclear-encoded 
mitochondrial proteins ATP5A or UQCRC2 (Fig. 3a and Supplementary Fig. 4a). This was 
associated with a compensatory increase in MT-CO1 and MT-CO2 mRNA levels 
(Supplementary Fig. 4b). In line with this, tigecycline treatment significantly impaired 
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mitochondrial respiration of CD34+ CML cells (Supplementary Fig. 4c).  Primary CD34+ 
CML cells were then cultured with 13C6-glucose for 24 hours in the absence or presence of 
tigecycline. A robust and significant decrease in glucose oxidation was noted in tigecycline-
treated cells, with a 2.8-3.4-fold decrease in the incorporation of 13C isotopes into citrate, 
glutamate and aspartate (Fig. 3b-d). Tigecycline had a broad effect on cellular metabolism as 
illustrated by a combined decrease in respiration and extracellular acidification rate 
(Supplementary Fig. 4c,d) indicative of a concurrent impairment of oxidative 
phosphorylation and glycolysis.  This was associated with a decrease in both PDH and PC 
relative activity (Supplementary Fig. 4e,f). Similarly, CD34+ CML cells treated with 
tigecycline displayed a significant decrease in the fraction of isotopologues with 2 or more 13C 
atoms following incubation with 13C5-glutamine and 13C16-palmitate (Supplementary Fig. 4g-
l). In tandem to blocking oxidative metabolism, tigecycline treatment decreased the overall 
steady-state levels of aspartate (Fig. 3d), in support of the anaplerotic role of oxidative 
metabolism in the LSCs-enriched population.  
 
Oxidative phosphorylation and anaplerosis are essential for growth and proliferation. Labelling 
of CD34+ CML cells with a fluorescent cell division tracker revealed that tigecycline alone, or 
in combination with imatinib, strongly impaired proliferation of primary CD34+ CML cells, 
whereas imatinib alone had only a moderate effect, in line with its preferential effect on 
differentiated CD34- cells (Fig. 3e). Furthermore, treatment with imatinib or tigecycline alone 
decreased the number of short-term CML CFC, with their combined application effectively 
eliminating colony formation (Fig. 3f,g). This effect on colony growth correlated with an 
increase in cell death, measured by Annexin V staining (Supplementary Fig. 5a,b). 
Importantly, neither drug, alone or in combination, had a significant effect on normal, non-
leukaemic CFCs, affirming a potential therapeutic window (Fig. 3h). Thus far, our studies 
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suggest that the combined inhibitory effect of tigecycline and imatinib on CFCs may result 
from the effect of the drugs on two distinct populations, where imatinib targets more mature 
progenitors, while tigecycline targets the more oxidative, long-term LSCs. To test this 
hypothesis, LTC-IC assay was performed: CD34+ CML cells were treated once with imatinib 
or tigecycline, alone or in combination, followed by liquid culture for 5 weeks prior to placing 
them in semi-solid medium. This ensures selective measurements of the functional capacity of 
long-term LSCs, since short-term progenitor cells lose their colony forming potential during 
the 5 weeks culture. This stringent in vitro stem cell assay revealed that while imatinib was 
ineffective, tigecycline-mediated inhibition of oxidative metabolism significantly decreased 
CML LSC potential (Fig. 3i). Similar findings were observed when the mitochondrial complex 
I inhibitor phenformin was used (Supplementary Fig. 5c,d). 
 
To further assess the clinical relevance of these findings, we moved to a robust 
xenotransplantation model of human CML. Sub-lethally irradiated immuno-compromised 
mice were transplanted with CD34+ human CML cells. Six weeks later, engraftment was 
assessed by recording the percentage of cells expressing human leukocyte common antigen 
(CD45+) from the total peripheral leukocytes in the blood (Fig. 4a). After ensuring equivalent 
and sufficient engraftment of human cells in all mice (Supplementary Fig. 6a), mice were 
treated daily from 6 weeks post-transplantation for a period of 4 weeks with vehicle only, 
tigecycline (escalating doses of 25-100 mg.kg-1: see Methods), imatinib (100 mg.kg-1) or both 
drugs combined (Fig. 4a). In all experimental arms, no changes in body or spleen weight or 
signs of toxicity were observed during treatment and total bone marrow cellularity was 
unaffected, confirming excellent tolerability (Supplementary Fig. 6b-d). Importantly, the 
decreased level of mitochondria-encoded proteins was used as a pharmacodynamic biomarker 
to demonstrate on-target action of tigecycline in vivo (Supplementary Fig. 6e). Following 
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treatment, bone marrow cells were extracted and analysed by flow cytometry for the expression 
of the human antigens CD45 (leukocytes), CD34 (progenitors and stem cells) and CD38 (to 
distinguish between CD34+CD38+ progenitors and CD34+CD38- LSCs). The majority of bone 
marrow cells were non-leukaemic host cells (human CD45-) and, as indicated above, were 
unaffected by the treatment (Fig. 4b and Supplementary Fig. 7a). In contrast, the total number 
of CML-derived CD45+ cells in the bone marrow was decreased, though marginally, in 
tigecycline treated mice and significantly in mice treated with imatinib (Supplementary Fig. 
7b). Importantly, in the combination arm, the CML burden was further decreased, and when 
only undifferentiated bone marrow CD45+CD34+ CML cells were analysed, these results were 
even more pronounced (Fig. 4b,c and Supplementary Fig. 7a,b). The most striking effect 
though was seen within the more primitive human LSCs population. Whereas imatinib alone 
only marginally (and insignificantly) decreased the number of CD45+CD34+CD38- CML cells, 
the combination treatment eliminated 95% of these cells (Fig. 4d).  
 
Experiments using cord blood CD34+ cells showed that both imatinib and tigecycline, either 
alone or in combination, had a marginal effect on engrafted normal blood cells 
(Supplementary Figure 8a-c). Finally, an additional two cohorts of mice were transplanted 
with CD34+ CML cells and treated as before. To investigate whether the combination of 
tigecycline and imatinib slowed the rate of relapse, both cohorts were then left untreated for an 
additional two (experiment 1) or three (experiment 2) weeks. Bone marrow analysis following 
drug withdrawal demonstrated that while mice treated with imatinib as a single agent showed 
signs of relapse (with the number of leukaemic cells similar to untreated mice), the vast 
majority of mice treated with the combination of tigecycline and imatinib sustained low 
numbers of LSCs in the bone marrow (Fig. 4e,f).  
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Taken together, our findings indicate that primitive CML stem/progenitor cells are highly 
susceptible to the inhibition of oxidative phosphorylation, while CD34+ normal cells are not. 
This previously unknown metabolic vulnerability shown here represents a therapeutic target 
for treatment with the FDA-approved mitochondrial translation inhibitor tigecycline. Finally, 
in vivo, combining tigecycline treatment with the standard-of-care drug, imatinib, produces a 
selective cytotoxic effect on CD34+ CML and on more primitive LSCs at clinically 
administrable doses.  
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FIGURE LEGENDS 
Figure 1 Primitive CML cells show an increase in oxidative metabolism compared to 
differentiated counterparts. (a) Comparative steady-state metabolomics analysis of patient-
matched CD34+ and CD34- CML cells measured by LC-MS. Mean, n=4 patients. (b) 
Representative respirometry output in CD34+ and CD34- CML cells. Mean ± S.D. (c) Basal 
mitochondrial oxygen consumption rate (OCR) of CD34+ and CD34- CML cells. Mean ± 
S.E.M. n=4 patient samples. (d) Relative isotopologue distribution of indicated metabolites in 
CD34+ and CD34- CML cells measured by LC-MS following 24 hours incubation with 13C6-
labelled glucose. Acetyl-CoA could not be detected by LC-MS in our experimental conditions. 
Mean ± S.E.M. n=3 patient samples. FC, fold change of glucose-derived (13C ≥ 2) metabolite 
abundance relative to CD34- CML cells. PDH, Pyruvate dehydrogenase; PC, Pyruvate 
carboxylase. P values were calculated with paired Student’s t-test. 
 
Figure 2 Enhanced mitochondrial metabolic activity in primitive CML cells compared to 
normal undifferentiated haemopoietic cells. (a-c) Relative isotopologue distribution of (a) 
citrate, (b) glutamate and (c) aspartate in CD34+ CML and CD34+ normal cells measured by 
LC-MS following 24 hours incubation with 13C6-labelled glucose. Mean ± S.E.M. n=5 patient 
and normal samples. FC, Fold change of glucose-derived (13C ≥ 2) metabolite abundance 
relative to CD34+ normal cells. P values were calculated by unpaired Student’s t-test. (d) 
Representative respirometry output in CD34+ CML and CD34+ normal cells. Mean ± S.D. (e) 
Basal mitochondrial OCR. Mean ± S.E.M. n=9 patient samples and n=4 normal samples. P 
values were calculated by unpaired Student’s t-test. (f) Representative histograms of 
Mitotracker Green-labelled CD34+CD38- CML cells (blue) and CD34+CD38- normal cells 
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(red). (g) Mitochondrial content of CD34+CD38- CML cells and CD34+CD38- normal cells 
was determined from the geometric mean of Mitotracker Green-labelled cells. Mean ± S.E.M. 
n=3 patient and 3 normal samples. P values were determined by one sample t-test. (h) 
Representative histograms of TMRM-labelled CD34+CD38- CML (blue) and CD34+CD38- 
normal (red) cells. (i) Mitochondrial membrane potential of CD34+CD38- CML cells and 
CD34+CD38- normal cells was determined from the geometric mean of TMRM-labelled cells. 
Mean ± S.E.M. n=3 patient and 3 normal samples. FC, fold change relative to normal cells. P 
values were determined by one sample t-test. (j-l) Relative isotopologue distribution of (j) 
citrate, (k) glutamate and (l) aspartate in CD34+CD38- CML and CD34+CD38- normal cells 
measured by LC-MS following 24 hours incubation with 13C6-labelled glucose. n=1 patient 
sample.  
 
Figure 3 Inhibition of aberrant oxidative metabolism targets CML progenitors and LSCs. (a) 
Protein expression in CD34+ CML cells following a 72 hours in vitro treatment with tigecycline 
(2.5 µM). n=1 patient sample. (b-d) Relative isotopologue distribution of (b) citrate, (c) 
glutamate and (d) aspartate in CD34+ CML cells measured by LC-MS following 24 hours 
incubation with 13C6-labelled glucose in the presence or absence of tigecycline (2.5 µM). Mean 
± S.E.M. n=3 patient samples. (e) Representative flow cytometry histograms obtained from 
cellular division tracking of CellTrace Violet-stained CD34+ CML cells following 72 hours 
treatment with vehicle only, tigecycline (2.5 µM), imatinib (2 µM) and combination (2.5 µM 
+ 2 µM). (f) Representative images of colonies and (g) colony numbers following 3 days drug 
treatment of CD34+ CML cells. Mean ± S.E.M. n=4 patient samples. (h) Colony number of 
CD34+ normal cells following 72 hours drug treatment with the indicated drugs. Mean ± S.E.M. 
n=4 normal samples. (i) Number of colonies measured by LTC-IC assay in CD34+ CML cells. 
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Mean ± S.E.M. n=5 patient samples. FC, Fold change of glucose-derived (13C ≥ 2) metabolite 
abundance relative to tigecycline-treated CD34+ CML cells. TIG, tigecycline; IM, imatinib; 
Combo, combination. P values were calculated by paired Student’s t-test. 
 
Figure 4 Inhibition of oxidative metabolism eliminates xenotransplanted human CML LSCs. 
(a) Diagram of experimental design. The pre-treatment engraftment levels of CML cells in 
mice were assessed by monitoring the percentage of human CD45+ circulating leukocytes using 
flow cytometry. (b) Representative analyses of human CD45 and CD34 expression in murine 
bone marrow was used to assess engrafted CML cells following the indicated treatment. (c) 
Number of human CD34+ and (d) human CD34+CD38- CML cells remaining in the bone 
marrow following in vivo drug treatment. (e) Number of human CD34+ and (f) human 
CD34+CD38- CML cells remaining in the bone marrow following 2 (experiment 1) or 3 
(experiment 2) weeks of drug discontinuation. n≥5 mice per treatment arm. TIG, tigecycline; 
IM, imatinib. P values were calculated by unpaired Student’s t-test on logarithmic transformed 
variables to meet the assumption of normality. 
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